Clinical Trial Update: Expanded Access Study of Satraplatin Plus Prednisone in Patients With Hormone Refractory Prostate Cancer (HRPC) [Phase 3]

View source ↗

Summary

Expanded Access Phase 3 study of satraplatin plus prednisone in hormone-refractory prostate cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• PREDNISONE (Prednisone)
• satraplatin (satraplatin)

Snippet

Sponsor: Agennix | Conditions: Prostate Cancer | Phase 3 | Status: TERMINATED